Compound ID | 263
Class: Glycopeptide
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Membrane-active agent |
| Target Pathogen: | Active against Enterococcus faecalis, Staphylococci, and Streptococci |
| Description: | A vancomycin covalently bonded to a 4-aminoquinoline; Meunier B. Vancomyquine PA1409: A New Hybrid Antibacterial Molecule. F1-2031 49th-ICAAC 2009 |
| Institute where first reported: | PALUMED, France |
| Year first mentioned: | 2009 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
| Reason dropped: | Specific toxicity issues resulted in the closure of the antibioquines program in 2010 |
| External links: | |
| Citations: |
|
| Patent: | WO2010089341A1 |